Evidence map›Paper›PMID 28071894›Full record

ArticleAccounts of chemical research2017

Noninvasive Monitoring of Blood Glucose with Raman Spectroscopy.

Rishikesh Pandey, Santosh Kumar Paidi, Tulio A Valdez, Chi Zhang, Nicolas Spegazzini, Ramachandra Rao Dasari, Ishan Barman

Open access · greenAbstract read
In one paragraph

Article in Accounts of chemical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
33.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 274 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Rishikesh PandeyConnecticut Children's Innovation Center, University of Connecticut Health , Farmington, Connecticut 06032, United States.
Santosh Kumar PaidiDepartment of Mechanical Engineering, Johns Hopkins University , Baltimore, Maryland 21218, United States.
Tulio A ValdezConnecticut Children's Innovation Center, University of Connecticut Health , Farmington, Connecticut 06032, United States.
Chi ZhangDepartment of Mechanical Engineering, Johns Hopkins University , Baltimore, Maryland 21218, United States.
Nicolas SpegazziniLaser Biomedical Research Center, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States.
Ramachandra Rao DasariLaser Biomedical Research Center, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States.
Ishan BarmanDepartment of Mechanical Engineering, Johns Hopkins University , Baltimore, Maryland 21218, United States.ORCID 0000-0003-0800-0825
Johns Hopkins University · USMassachusetts Institute of Technology · USUniversity of Connecticut · US

Funding

Wide-Field Short-Wave Infrared (SWIR) multiphoton (MP) tissue imagingP41EB015871 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SO, PETER T. · 2012 to 2021
$11.3M
NIBIB NIH HHS P41 EB015871
6 · The paper itself

Abstract

The successful development of a noninvasive blood glucose sensor that can operate reliably over sustained periods of time has been a much sought after but elusive goal in diabetes management. Since diabetes has no well-established cure, control of elevated glucose levels is critical for avoiding severe secondary health complications in multiple organs including the retina, kidney and vasculature. While fingerstick testing continues to be the mainstay of blood glucose detection, advances in electrochemical sensing-based minimally invasive approaches have opened the door for alternate methods that would considerably improve the quality of life for people with diabetes. In the quest for better sensing approaches, optical technologies have surfaced as attractive candidates as researchers have sought to exploit the endogenous contrast of glucose, notably its absorption, scattering, and polarization properties. Vibrational spectroscopy, especially spontaneous Raman scattering, has exhibited substantial promise due to its exquisite molecular specificity and minimal interference of water in the spectral profiles acquired from the blood-tissue matrix. Yet, it has hitherto been challenging to leverage the Raman scattering signatures of glucose for prediction in all but the most basic studies and under the least demanding conditions. In this Account, we discuss the newly developed array of methodologies that address the key challenges in measuring blood glucose accurately using Raman spectroscopy and unlock new prospects for translation to sustained noninvasive measurements in people with diabetes. Owing to the weak intensity of spontaneous Raman scattering, recent research has focused on enhancement of signals from the blood constituents by designing novel excitation-collection geometries and tissue modulation methods while our attempts have led to the incorporation of nonimaging optical elements. Additionally, invoking mass transfer modeling into chemometric algorithms has not only addressed the physiological lag between the actual blood glucose and the measured interstitial fluid glucose values but also offered a powerful tool for predictive measurements of hypoglycemia. This framework has recently been extended to provide longitudinal tracking of glucose concentration without necessitating extensive a priori concentration information. These findings are advanced by the results of recent glucose tolerance studies in human subjects, which also hint at the need for designing nonlinear calibration models that can account for subject-to-subject variations in skin heterogeneity and hematocrit levels. Together, the emerging evidence underscores the promise of a blood withdrawal-free optical platform-featuring a combination of high-throughput Raman spectroscopic instrumentation and data analysis of subtle variations in spectral expression-for diabetes screening in the clinic and, ultimately, for personalized monitoring.

Indexed as

Blood GlucoseCalibrationHumansHydrogelsHypoglycemiaSkinSpectrum Analysis, RamanBlood GlucoseHydrogels

Identifiers

PMID28071894
PMCPMC5896772
OpenAlexW2570632582

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.